An intranasal vector vaccine can be used to mount protective responses against SARS-CoV-2 in the respiratory tract

A team led by CITF-funded researcher Dr. Jun Liu at the University of Toronto have demonstrated that a novel intranasal COVID-19 vaccine product can induce robust mucosal and systemic immune responses in a mouse model of SARS-CoV-2 infection.